BGE-102 An oral, brain-penetrant NLRP3 inhibitor in Phase 2 development for cardiovascular risk and planned clinical development for diabetic macular edema.
Visit productCosigns Received
Be the first Cosign
Put your name behind BGE-102.
Add it to your Products I use list and share why you use it.